CARD-Studie – Bedeutung für die Therapie des fortgeschrittenen Prostatakarzinoms
Published 2020 View Full Article
- Home
- Publications
- Publication Search
- Publication Details
Title
CARD-Studie – Bedeutung für die Therapie des fortgeschrittenen Prostatakarzinoms
Authors
Keywords
-
Journal
AKTUELLE UROLOGIE
Volume -, Issue -, Pages -
Publisher
Georg Thieme Verlag KG
Online
2020-09-24
DOI
10.1055/a-1247-4155
References
Ask authors/readers for more resources
Related references
Note: Only part of the references are listed.- Ziel: 20 statt 50! Aktuelle Daten zum Zielwert der Testosteronsenkung und die Forschung hierüber seit erster „LH-RH“ (GnRH)-Analoga-Gabe an Patienten vor 40 Jahren
- (2020) Peter Hammerer et al. AKTUELLE UROLOGIE
- Frühe vs. spätere Therapie mit Abirateron plus Prednison bei chemotherapie-naiven, asymptomatischen bis mild symptomatischen Patienten mit metastasiertem CRPC nach Androgendeprivation
- (2020) Axel S. Merseburger et al. AKTUELLE UROLOGIE
- Therapie des metastasierten kastrationsresistenten Prostatakarzinoms
- (2020) G. von Amsberg et al. UROLOGE
- Cabazitaxel versus Abiraterone or Enzalutamide in Metastatic Prostate Cancer
- (2019) Ronald de Wit et al. NEW ENGLAND JOURNAL OF MEDICINE
- LBA12_PRPROfound: Phase III study of olaparib versus enzalutamide or abiraterone for metastatic castration-resistant prostate cancer (mCRPC) with homologous recombination repair (HRR) gene alterations
- (2019) M Hussain et al. ANNALS OF ONCOLOGY
- Therapie des metastasierten Prostatakarzinoms im Wandel – neue Daten und offene Fragen
- (2019) P. Albers et al. UROLOGE
- Androgen receptor-targeted agents in the management of advanced prostate cancer
- (2019) Bertrand Tombal LANCET ONCOLOGY
- Optimal sequencing of enzalutamide and abiraterone acetate plus prednisone in metastatic castration-resistant prostate cancer: a multicentre, randomised, open-label, phase 2, crossover trial
- (2019) Daniel J Khalaf et al. LANCET ONCOLOGY
- Management of Patients with Advanced Prostate Cancer: The Report of the Advanced Prostate Cancer Consensus Conference APCCC 2017
- (2018) Silke Gillessen et al. EUROPEAN UROLOGY
- Abiraterone Alone or in Combination With Enzalutamide in Metastatic Castration-Resistant Prostate Cancer With Rising Prostate-Specific Antigen During Enzalutamide Treatment
- (2018) Gerhardt Attard et al. JOURNAL OF CLINICAL ONCOLOGY
- Radiographic progression with nonrising PSA in metastatic castration-resistant prostate cancer: post hoc analysis of PREVAIL
- (2017) A H Bryce et al. PROSTATE CANCER AND PROSTATIC DISEASES
- Trial Design and Objectives for Castration-Resistant Prostate Cancer: Updated Recommendations From the Prostate Cancer Clinical Trials Working Group 3
- (2016) Howard I. Scher et al. JOURNAL OF CLINICAL ONCOLOGY
- Enzalutamide Antitumour Activity Against Metastatic Castration-resistant Prostate Cancer Previously Treated with Docetaxel and Abiraterone: A Multicentre Analysis
- (2015) Klaus Brasso et al. EUROPEAN UROLOGY
- Enzalutamide After Docetaxel and Abiraterone Therapy in Metastatic Castration-Resistant Prostate Cancer
- (2014) Sebastian Christoph Schmid et al. ADVANCES IN THERAPY
- Antitumour activity of abiraterone acetate against metastatic castration-resistant prostate cancer progressing after docetaxel and enzalutamide (MDV3100)
- (2013) Y. Loriot et al. ANNALS OF ONCOLOGY
- Clinical activity of abiraterone acetate in patients with metastatic castration-resistant prostate cancer progressing after enzalutamide
- (2013) K. L. Noonan et al. ANNALS OF ONCOLOGY
- Clinical activity and tolerability of enzalutamide (MDV3100) in patients with metastatic, castration-resistant prostate cancer who progress after docetaxel and abiraterone treatment
- (2013) Sushil Badrising et al. CANCER
- Antitumour activity of enzalutamide (MDV3100) in patients with metastatic castration-resistant prostate cancer (CRPC) pre-treated with docetaxel and abiraterone
- (2013) D. Bianchini et al. EUROPEAN JOURNAL OF CANCER
- Enzalutamide in Castration-resistant Prostate Cancer Patients Progressing After Docetaxel and Abiraterone
- (2013) Andres Jan Schrader et al. EUROPEAN UROLOGY
- Prednisone plus cabazitaxel or mitoxantrone for metastatic castration-resistant prostate cancer progressing after docetaxel treatment: a randomised open-label trial
- (2010) Johann Sebastian de Bono et al. LANCET
Find the ideal target journal for your manuscript
Explore over 38,000 international journals covering a vast array of academic fields.
SearchBecome a Peeref-certified reviewer
The Peeref Institute provides free reviewer training that teaches the core competencies of the academic peer review process.
Get Started